(290 days)
Not Found
Not Found
No
The description focuses on the mechanical properties and delivery system of a physical stent, with no mention of AI/ML terms or functionalities.
Yes
The device is intended for "palliation of malignant neoplasms in the biliary tree" and is designed to "maintain patency of biliary ducts," which are therapeutic actions to alleviate symptoms or treat a condition.
No
The device is described as a stent and delivery system intended for "palliation of malignant neoplasms in the biliary tree" by maintaining patency of biliary ducts. This indicates a therapeutic function, not a diagnostic one.
No
The device description clearly states it is a system consisting of a nitinol stent and a delivery catheter, which are physical hardware components.
Based on the provided information, this device is not an IVD (In Vitro Diagnostic).
Here's why:
- Intended Use: The intended use is "for palliation of malignant neoplasms in the biliary tree." This describes a therapeutic intervention performed within the body to treat a condition.
- Device Description: The device is a physical stent and delivery system designed to be implanted in the biliary duct. This is a medical device used for treatment, not for testing samples in vitro (outside the body).
- Lack of IVD Characteristics: The description does not mention any components or processes related to analyzing biological samples (blood, urine, tissue, etc.) to diagnose, monitor, or screen for diseases or conditions.
IVD devices are used to perform tests on samples taken from the human body to provide information for diagnosis, monitoring, or screening. This device is a therapeutic implant.
N/A
Intended Use / Indications for Use
The Cordis Nitinol Stent and Delivery System is intended for palliation of malignant neoplasms in the biliary tree.
Product codes (comma separated list FDA assigned to the subject device)
78 FGE
Device Description
The subject device is a system consisting of a self-expanding, open mesh, nitinol stent preloaded onto a sheathed delivery catheter. The delivery system is designed to deliver the stent to the stricture site via transhepatic access. Once positioned at the sheath is withdrawn and the stent is released. Upon release, the stent expands and conforms to the inner lumen of the biliary duct. The stent is designed to maintain patency of biliary ducts which have been obstructed by malignant neoplasms.
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
Biliary tree / biliary ducts
Indicated Patient Age Range
Not Found
Intended User / Care Setting
Not Found
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)
Nonclinical performance: The differences between the subject and predicate devices are minor and are not relevant to the ability of the subject device to palliate malignant neoplasms in the biliary tree. The descriptive characteristics are precise enough to demonstrate equivalence. Preclinical testing was conducted which confirmed the safe and effective performance and biocompatibility of the subject device. Comparative testing was also conducted which confirmed substantial equivalence of the subject and predicate devices.
Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)
Not Found
Predicate Device(s): If the device was cleared using the 510(k) pathway, identify the Predicate Device(s) K/DEN number used to claim substantial equivalence and list them here in a comma separated list exactly as they appear in the text. List the primary predicate first in the list.
Wallstent® Biliary Endoprosthesis with Unistep™ Delivery System, Symphony™ Nitinol Stent Transhepatic Biliary System, Bard® Memotherm® Nitinol Stent Transhepatic Biliary Endoprosthesis, PALMAZ™ Balloon-Expandable Stent, PALMAZ™ & PALMAZ-SCHATZ™ Balloon-Expandable Stent and Stent Delivery Systems, Long Medium PALMAZ-SCHATZ™ Balloon-Expandable Stent
Reference Device(s): Identify the Reference Device(s) K/DEN number and list them here in a comma separated list exactly as they appear in the text.
Not Found
Predetermined Change Control Plan (PCCP) - All Relevant Information for the subject device only (e.g. presence / absence, what scope was granted / cleared under the PCCP, any restrictions, etc).
Not Found
§ 876.5010 Biliary catheter and accessories.
(a)
Identification. A biliary catheter and accessories is a tubular flexible device used for temporary or prolonged drainage of the biliary tract, for splinting of the bile duct during healing, or for preventing stricture of the bile duct. This generic type of device may include a bile collecting bag that is attached to the biliary catheter by a connector and fastened to the patient with a strap.(b)
Classification. Class II (special controls). The device, when it is a bile collecting bag or a surgical biliary catheter that does not include a balloon component, is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 876.9.
0
DEC 1 8 1998
Cordis Nitinol Stent & Delivery System Cordis, a Johnson & Johnson Company
510(k) Premarket Notification
510(k) SUMMARY
| Submitter's name: | Cordis Corporation, a Johnson & Johnson Company
14201 NW 60th Avenue
Miami Lakes, Florida 33014 |
|----------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Contact person: | Joan Martin
Manager, Endovascular Regulatory Affairs
(908) 412-7250 |
| Date prepared: | March 2, 1998 |
| Trade name: | To be determined |
| Common name: | Biliary Stent and Delivery System |
| Classification name: | §876.5010 Biliary Cathether and Accessories |
| Predicate devices: | Wallstent® Biliary Endoprosthesis with Unistep™ Delivery
System
Symphony™ Nitinol Stent Transhepatic Biliary System
Bard® Memotherm® Nitinol Stent Transhepatic Biliary
Endoprosthesis
PALMAZ™ Balloon-Expandable Stent
PALMAZ™ & PALMAZ-SCHATZ™ Balloon-Expandable Stent
and Stent Delivery Systems
Long Medium PALMAZ-SCHATZ™ Balloon-Expandable Stent |
Device Description - The subject device is a system consisting of a self-expanding, open mesh, nitinol stent preloaded onto a sheathed delivery catheter. The delivery system is designed to deliver the stent to the stricture site via transhepatic access. Once positioned at the sheath is withdrawn and the stent is released. Upon release, the stent expands and conforms to the inner lumen of the biliary duct. The stent is designed to maintain patency of biliary ducts which have been obstructed by malignant neoplasms.
The Cordis Nitinol Stent and Delivery System is intended for palliation of Labeled Indication: malignant neoplasms in the biliary tree.
Technological Characteristics: The Cordis Nitinol Stent and Delivery System is substantially equivalent in design, function and intended use to currently marketed biliary stents. The subject and predicate stents have a tubular, open mesh design intended for palliation of malignant neoplasms in the biliary tree. The subject stent is self-expandable. The predicate stents are self-expandable or balloon expandable. Both stent types have been shown to be safe and effective. The subject and predicate stents
1
Cordis Nitinol Stent & Delivery System Cordis, a Johnson & Johnson Company
510(k) Premarket Notification
510(k) Summary (continued)
and delivery systems are constructed of biocompatible materials. The subject and predicate stents are delivered percutaneously via a delivery system. The subject delivery system is a sheathed delivery system. The predicate delivery systems are either sheathed delivery systems or balloon delivery systems. Both system types have been shown to be safe and effective.
The range of lengths and diameters of the subject and predicate stents are comparable and are intended to meet clinical need.
Nonclinical performance: The differences between the subject and predicate devices are minor and are not relevant to the ability of the subject device to palliate malignant neoplasms in the biliary tree. The descriptive characteristics are precise enough to demonstrate equivalence. Preclinical testing was conducted which confirmed the safe and effective performance and biocompatibility of the subject device. Comparative testing was also conducted which confirmed substantial equivalence of the subject and predicate devices.
Conclusion: The Cordis Nitinol Stent and Delivery System is substantially equivalent to currently marketed predicate devices.
2
Image /page/2/Picture/1 description: The image is a black and white logo for the U.S. Department of Health & Human Services. The logo features a circular design with the text "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" arranged around the perimeter. Inside the circle is an abstract symbol that resembles a stylized caduceus, with three intertwined figures representing the human services aspect of the department.
Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850
DEC 1 8 1998
Ms. Joan Martin Manager, Regulatory Affairs Cordis Corporation P.O. Box 4917 Warren, New Jersey 07059
Re: K980823
Cordis Nitinol Stent and Delivery System for use in biliary ducts Regulatory Class: II 21 CFR §876.5010 Product Code: 78 FGE Dated: October 28, 1998 Received: October 29, 1998
Dear Ms. Martin:
We have reviewed your Section 510(k) notification of intent to market the device referenced above and we have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act). You may, therefore, market the device, subject to the general controls provisions of the Act and the limitations described below. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.
The Office of Device Evaluation has determined that there is a reasonable likelihood that this device will be used for an intended use not identified in the proposed labeling and that such use could cause harm. Therefore, in accordance with Section 513(i)(1)(E) of the Act, the following limitation must appear in the Warnings section of the device's labeling:
The safety and effectiveness of this device for use in the vascular system have not been established.
Furthermore, the indication for biliary use must be prominently displayed in all labeling, including pouch, box, and carton labels, instructions for use, and other promotional materials, in close proximity to the trade name, of a similar point size, and in bold print.
3
If your device is classified (see above) into either class II (Special Controls) or class III (Premarket Approval), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 895. A substantially equivalent determination assumes compliance with the Current Good Manufacturing Practice requirements, as set forth in the Ouality System Regulation (OS) for Medical Devices: General regulation (21 CFR Part 820) and that, through periodic QS inspections, the Food and Drug Administration (FDA) will verify such assumptions. Failure to comply with the GMP regulation may result in regulatory action. In addition, FDA may publish further announcements concerning your device in the Federal Register. Please note: this response to your premarket notification submission does not affect any obligation you might have under sections 531 through 542 of the Act for devices under the Electronic Product Radiation Control provisions, or other Federal laws or regulations.
The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and permits your device to proceed to the market. This letter will allow you to begin marketing your device as described in your 510(k) premarket notification if the limitation statement above is added to your labeling, as described.
Please note that the above labeling limitations are required by Section 513(i)(1)(E) of the Act. Therefore, a new 510(k) is required before these limitations are modified in any way or removed from the device's labeling.
If you desire specific information about the application of other labeling requirements to your device (21 CFR Part 801 and additionally 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4616. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its internet address "http://www.fda.gov/cdrh/dsma/dsmamain.html".
Sincerely yours,
Sincerely yours,
Susan Alpert, Ph.D., M.D. Director Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
4
510(k) Number (if known): To be Assigned
Cordis Nitinol Stent and Delivery System Device Name:
Indications for Use:
The Cordis Nitinol Stent and Delivery System is intended for palliation of malignant neoplasms in the biliary tree.
(PLEASE DO NOT WRITE BELOW THIS LINE - CONTINUE ON ANOTHER PAGE IF NEEDED)
------------------------------------------------------------------------------------------------------------------------------------------------------------------------------Concurrence of CDRH, Office of Device Evaluation (ODE)
Prescription Use i (Per 21 CFR 801.109)
OR
Over-the-Counter Use __
(Optional Format 1/2/96)
(Division Sign-Off) Division of Reproductive, Abdominal, ENT, and Radiological Devices
510(k) Number: X980823/S^{ricez}